Research programme: hepatitis B virus therapy - AvexaAlternative Names: AM-491; AVX-491
Latest Information Update: 21 Dec 2006
At a glance
- Originator Avexa
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Hepatitis B
Most Recent Events
- 31 May 2004 Avexa Ltd., has been established as a spin-out of AMRAD's anti-infectives drug portfolio
- 22 Jan 2003 This programme is still in active development
- 25 Sep 2000 Preclinical development for Hepatitis B in Australia (Unknown route)